New program offers lifesaving combo for advanced melanoma patients
NCT ID NCT04489433
First seen Dec 18, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This program gives adults with a specific type of advanced melanoma (BRAF mutation-positive) access to two targeted drugs, trametinib and dabrafenib, which work together to shrink tumors and control the disease. Participants must have melanoma that has spread or cannot be removed by surgery. The goal is to provide treatment when no other options are available, but it is not a cure—patients need ongoing medication to manage their condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.